Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8281)	1/14/1999 8:23:00 AM
From: Cacaito	Read Replies (1) \| Respond to of 17367

"IC14 to enter clinical trials" means future Phase I, Xoma is far ahead. "IC14 is an antibody blocks CD14" this is an approach leaa broad than Bpi, and more like (not identical)what E5, centoxin, Bayer, synergen tried and failed on. Of course, the final proof is the clinical trials, again they are going to begin Phase I. And, it could bring another combination posibility with Bpi in the future. The other failure candidates will probably be reinvestigated once there is one of them approved. Bpi will be the first (caveat, my wish). Psoriasis trial is a phase I, going into Phase I/II (meaning phase I again). Xoma/GNE Phase II is completed, next step is III, if they have good data, last press release in the subject seems like yes they do. Again, xoma is ahead. Ligand is the main thread, their product is a small moecule for oral delivery (vs xoma's and Icos' monoclonal antibodies which are usually for intramuscular injection), if effective Lgnd's will be the easy leader, they are in phase I.